ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ORMP vs ADAG // EV/EBITDA & P/E VALUATION

Oramed Pharmaceuticals Inc. (NASDAQ) VS. Adagene Inc. (NASDAQ) • 15-METRIC TALLY: ORMP 3 — ADAG 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ORMP VS. ADAG) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ORMP ADAG SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 0.70% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -7.80% -35.00% +27.20 ORMP /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -5.20% -8.85% +3.65 ORMP /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin 3.80% -60.00% +63.80 ORMP /net-margins <GO>
Revenue Growth (YoY) — 180.00% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 5/9 -2.00 ADAG /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 37.0 43.5 -6.57 ADAG /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $176.0M $177.0M -$1.1M ADAG /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ORMP REV ADAG REV ORMP GROSS % ADAG GROSS % ORMP FCF ADAG FCF
FY 2025 $2.0M $7.7M 0.7% — -$9.2M -$15.7M
FY 2024 $0 $103.2K — — -$8.4M -$29.7M
FY 2023 $1.3M $18.1M — — -$10.3M -$28.5M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ORMP // BETA —
ADAG // BETA —